US Federal House Bill HR1295

US Federal 2025-2026 Regular Session

• Committee Review: 5/15/26

Caption

Expressing support for the designation of May 17, 2026, as "DIPG Awareness Day" to raise awareness and encourage research into cures for diffuse intrinsic pontine glioma (DIPG) and pediatric cancers in general.

Summary

H. Res. 1295 is a House resolution expressing support for designating May 17, 2026, as “DIPG Awareness Day.” The resolution is focused on diffuse intrinsic pontine glioma, a rare and aggressive pediatric brain cancer, and it frames the observance as a way to increase public awareness of the disease and the urgent need for better treatments and cures. It also places DIPG in the broader context of pediatric cancer, emphasizing that brain tumors are a leading cause of cancer death in children and that DIPG has an especially poor prognosis. The resolution does not create a new legal program or mandate spending; instead, it is a statement of congressional support and encouragement. It calls on the public to learn more about DIPG and the challenges facing pediatric cancer research, supports expanded research into understanding and treating DIPG, and encourages both public and private research funders to consider mortality rate and life-years lost as important factors in grant decisions. The measure is currently a symbolic resolution referred to the House Committee on Energy and Commerce.

Impact

Because this is a resolution rather than a bill, it does not directly amend state law or federal statutory law, and it does not impose regulatory requirements on states, health systems, or private parties. Its practical effect would be limited to raising awareness and potentially influencing research priorities, philanthropic attention, and federal or private grantmaking criteria related to pediatric cancer and DIPG. Any downstream policy impact would be indirect, through advocacy and funding emphasis rather than legal change.

Sentiment

The overall sentiment reflected in the text is strongly supportive and urgent. The resolution is bipartisan in sponsorship and is framed around a severe pediatric health need, with repeated emphasis on the high mortality rate, short survival time, and lack of progress over decades. The tone suggests broad sympathy for affected children and families and a shared desire to accelerate research and awareness.

Contention

There is little evident opposition in the available materials, and no committee transcript or vote record is provided to show active debate. The only potential point of policy discussion is the resolution’s encouragement that grantmakers weigh mortality rate and life-years lost in funding decisions, which could raise questions about how research priorities should be set and whether rare pediatric cancers should receive special consideration. Otherwise, the measure appears noncontroversial and commemorative in nature.